Phase 1, Open-Label, Multicenter, Dose Escalation Study of mRNA-2752, a Lipid Nanoparticle Encapsulating mRNAs Encoding Human OX40L, IL-23, and IL-36γ, for Intratumoral Injection Alone and in Combination with Immune Checkpoint Blockade.
The clinical study will assess the safety and tolerability of escalating intra-tumoral doses of mRNA-2752 in participants with relapsed/refractory solid tumor malignancies or lymphoma.
Metastatic or advanced tumors Including:
- TNBC 2 line or >
- HNSCC 3 line or >
- NHL 3 line or >
- Urothelial PD-L-, 1st line
- Urothelial 2nd line
- Cutaneous melanoma
Inclusions/Exclusions: Measurable disease RECIST or Cheson 2016 criteria. ECOG 0-1.